Cited by 147Digital Mental Health InterventionsMobile Health and mHealth ApplicationsHealth, Technology, Consumer Behavior

Digital Therapeutics: An Integral Component of Digital Innovation in Drug Development

Sverdlov, Oleksandr, van Dam, Joris, Hannesdottir, Kristin, Thornton‐Wells, Tricia·2018·Clinical Pharmacology & Therapeutics

Abstract

Digital therapeutics represent a new treatment modality in which digital systems such as smartphone apps are used as regulatory‐approved, prescribed therapeutic interventions to treat medical conditions. In this article we provide a critical overview of the rationale for investing in such novel modalities, including the unmet medical needs addressed by digital therapeutics and the potential for reducing current costs of medical care. We also discuss emerging pathways to regulatory approval and how innovative business models are enabling further growth in the development of digital therapeutics. We conclude by providing some recent examples of digital therapeutics that have gained regulatory approval and highlight opportunities for the near future.

Integrity signals

Registry

Crossref · 10.1002/cpt.1036

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The US Preventive Services Task Force and Agency for Healthcare Research and Quality guidelines have recommended routine screening for depression in healthcare settings to address the under-recognition of depression.

    “Over the last two decades, the US Preventive Services Task Force and Agency for Healthcare Research and Quality guidelines have recommended routine screening for depression in healthcare settings to address the under-recognition of depression.23”

    From Digital health technologies and major depressive disorder (2023) · cites this paper as [23]

  • VitalSign 6 software facilitates treatment selection, implementation, and revision for patients with depression.

    “VitalSign 6 software facilitates treatment selection, implementation, and revision for patients with depression.23”

    From Digital health technologies and major depressive disorder (2023) · cites this paper as [23]

  • The VitalSign 6 software can be augmented by other models of care (eg, mental health navigation and behavioral activation teletherapy) and offers the potential to add-on research and quality improvement projects.

    “The software can be augmented by other models of care (eg, mental health navigation and behavioral activation teletherapy) and offers the potential to add-on research and quality improvement projects.23”

    From Digital health technologies and major depressive disorder (2023) · cites this paper as [23]

  • VitalSign 6 is an EHR-integrated web-based iPad app designed for use in clinics that facilitates screening and diagnosis in patients with depression using the PHQ-2.

    “VitalSign 6 is an EHR-integrated web-based iPad app designed for use in clinics that facilitates screening and diagnosis in patients with depression using the two-item version of the Patient Health Questionnaire (PHQ-2).”

    From Digital health technologies and major depressive disorder (2023) · cites this paper as [23]

  • Screening efforts in VitalSign 6 are focused on identifying patients with depression, and there are no additional screening assessments for those who screen negative on the PHQ-2; thus, patients with current suicidality who do not have significant depressive symptoms may be missed.

    “Screening efforts are focused on identifying patients with depression, and there are no additional screening assessments for those who screen negative on the PHQ-2; thus, patients with current suicidality who do not have significant depressive symptoms may be missed.”

    From Digital health technologies and major depressive disorder (2023) · cites this paper as [23]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sverdlov, O., van Dam, J., Hannesdottir, K., & Thornton‐Wells, T.
Affiliations
  • Novartis (United States) (US)
  • Novartis Institutes for Biomedical Research Cambridge Massachusetts USA
Corresponding author
Sverdlov, Oleksandr
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2018-02-23
Volume
104
Issue
1
Pages
72-80
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2793903251
Cited by
147
References
50
Citations by year
2026: 11 · 2025: 16 · 2024: 19 · 2023: 31 · 2022: 37 · 2021: 11 · 2020: 13 · 2019: 6 · 2018: 3
FWCI
1.12
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Health Sciences › Health Professions › Health Information Management › Health, Technology, Consumer Behavior
Keywords
digital therapeutics, drug development, mobile application, regulatory approval, unmet medical needs, health care costs, business models, digital health
MeSH terms
Smartphone, Drug Development, Clinical Trials as Topic, Health Services Needs and Demand, Humans, Drug Approval, Precision Medicine, Inventions, Mobile Applications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review